NanoVibronix

NanoVibronix's UroShield Completes Pilot Phase for UTI Prevention

- NanoVibronix has successfully completed the pilot phase of a randomized controlled trial for UroShield, a device designed to prevent catheter-associated urinary tract infections (UTIs). - The pilot phase, conducted at the University of Michigan, focused on refining recruitment strategies and assessing data collection tools for the full study. - The upcoming full study will enroll approximately 300 participants and will run concurrently with preparations for UroShield's potential US market launch, pending FDA 510K clearance. - UroShield utilizes low-intensity ultrasonic waves to prevent bacterial colonization on urinary catheters, potentially reducing UTIs and improving patient quality of life.